Perspective · 10 Sep 2026
Conference abstractPublished 15 Oct 2013
Engineering pancreatic islets with exogenous immunomodulatory proteins for the induction of allogeneic tolerance
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Type I diabetes mellitus is an immune-mediated disease and characterized by loss of insulin producing beta cells in pancreas leading to insulin deficiency. Autoreactive T cells play a key role in beta-cell destruction during the disease progression. Selective elimination of autoreactive T cells and replacement of destructed islet cells are the ultimate goal for treatment of type 1 diabetes. Allogeneic islet transplantation may be considered as a therapeutic approach for the treatment of type 1 diabetes. However clinical application of this approach is limited by allograft rejection. The rejection is initiated by alloreactive T cells beside long-term use of immunosuppressive medications which are associated with a broad range of side effects. Therefore, novel approaches that control rejection in the absence of chronic immunosuppression will have significant impact on the field of islet transplantation. Activated T cells up-regulates Fas and FasL on their cell surface and upon re-activation with same antigen they become sensitive to FasL-mediated apoptosis. Therefore, selective elimination of alloreactive T cells will not only eliminate the need to use of immunosuppressive drugs but also protects allogeneic islet graft from rejection with intact immune response to unrelated antigens or pathogens. Towards this end, we have constructed and produced a novel form of FasL protein which is chimeric with streptavidin (SA-FasL). We have engineered pancreatic islets using biotin as a bridge to display SA-FasL chimeric protein on the surface of allogeneic islets in a rapid and efficient manner without any unfavorable effect on the function of islets. Transplantation of SA-FasL-engineered islets into diabetic allogeneic recipients resulted in tolerance and treatment of diabetes. Therefore, the direct display of immunological ligands on the surface of islets serves as a rapid, efficient, and clinically applicable approach for immunomodulation with implications in clinical islet transplantation.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Esma S. Yolcu”
